Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis.
MRI
prostate disease
urological tumours
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
10 12 2021
10 12 2021
Historique:
entrez:
11
12
2021
pubmed:
12
12
2021
medline:
8
3
2022
Statut:
epublish
Résumé
The introduction of multiparametric MRI (mpMRI) has improved almost every aspect of the prostate cancer diagnostic pathway. However, the novel imaging technique, prostate-specific membrane antigen positron emission tomography (PSMA PET) may have demonstrable accuracy in detecting and staging prostate cancer. Here, we describe a protocol for a systematic review and meta-analysis comparing mpMRI to PSMA PET for the diagnosis of suspected prostate cancer. A systematic search of MEDLINE, EMBASE, PubMed and Cochrane databases will be conducted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed for screening, data extraction, statistical analysis and reporting. Included papers will be full-text articles providing original data, written in English articles and comparing the use of PSMA PET with mpMRI in the diagnosis of prostate cancer. All studies published between July 1977 and March 2021 will be eligible for inclusion. Study bias and quality will be assessed using Quadas-2 score. To ensure the quality of the reporting of studies, this protocol is written following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist. Ethical approval will not be required for this systematic review. Findings will be disseminated through peer-reviewed publications and presentations at both national and international conferences. CRD42021239296.
Identifiants
pubmed: 34893484
pii: bmjopen-2021-052277
doi: 10.1136/bmjopen-2021-052277
pmc: PMC8666885
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e052277Subventions
Organisme : Medical Research Council
ID : MR/S00680X/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JMN receives funding from the MRC. Simpson receives funding from the Royal Marsden Cancer Charity. HCW receives funding from Prostate Cancer UK, the Urology Foundation and Rosetrees Trust. AK, AF and ME have stock interest in Nuada Medical. ME acts as a consultant, trainer and proctor to Sonatherm; Angiodynamics; Exact Imaging.
Références
Clin Cancer Res. 2018 Dec 15;24(24):6300-6307
pubmed: 30139879
BMJ Open. 2020 Jan 27;10(1):e034611
pubmed: 31992607
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):859-873
pubmed: 32901351
Urology. 2019 Aug;130:1-12
pubmed: 30986486
BJU Int. 2019 Jul;124(1):1
pubmed: 31206999
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):596-611
pubmed: 33219368
BMJ. 2018 Dec 13;363:k5290
pubmed: 30545827
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Nucl Med. 2020 Apr;61(4):527-532
pubmed: 31562225
Curr Opin Oncol. 2018 May;30(3):189-196
pubmed: 29465429
Minerva Urol Nefrol. 2018 Aug;70(4):347-360
pubmed: 29388415
J Nucl Med. 2017 May;58(5):687-688
pubmed: 28408526
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Eur Urol Oncol. 2019 Feb;2(1):47-76
pubmed: 30929846
J Urol. 2015 Jan;193(1):87-94
pubmed: 25079939
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
J Nucl Med. 2017 Dec;58(12):1972-1976
pubmed: 28747524
AJR Am J Roentgenol. 2021 Mar;216(3):599-607
pubmed: 32755196